Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy

Inclusion criteria:

* Signed informed consent
* Man or woman between 18 and 85 years of age
* Patients who will be receiving at least 2 more cycles of moderately emetogenic chemotherapy
* Patients who are cognitively intact
* Performance Status of 60% or greater on the Karnofsky Scale
* Negative pregnancy test at screening visit in females of childbearing potential
* Use of appropriate contraceptive methods for females of childbearing potential during treatment (e.g. hormonal contraception, intrauterine device \[IUD\])

Exclusion Criteria:

* A history of psychiatric illness.
* A history of asthma and any other chronic respiratory illness.
* Subjects who, in the judgment of the investigator, are likely to be non-compliant or uncooperative during the study.
* Serious illnesses such as asthma, diabetes mellitus, active peptic ulcer disease, infection, cardiovascular disease or any other disease which may affect the oucome parameters of this study
* Abnormal liver function tests (ALT, AST or AP \> 2.5 x upper normal limit)
* Abnormal renal function (e.g. serum creatinine \> 2 x upper normal limit)
* Abnormal pulmonary function test which in the judgment of the investigator is incompatible with inhalation of the study drug
* Known intolerance/hypersensitivity to study drugs (THC, ondansetron or dexamethasone) or drugs of similar chemical structure or pharmacological profile
* History of addiction to alcohol or drugs
* Existing or intended pregnancy or lactation
* Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial